Dr. Jason Acker, MBA, PhD, Co-founder of PanTHERA CryoSolutions
Cell and gene therapies (CGTs) are reshaping medicine. Hundreds of clinical trials are underway worldwide, and the first wave of commercial therapies is already changing the…
Continue Reading
We're excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Pamela Tenaerts, Chief Medical Officer at Medable. Tenaerts talks about how they…
Continue Reading
What You Should Know:
– The Centers for Medicare & Medicaid Services (CMS) launches its Cell and Gene Therapy (CGT) Access Model, a new approach to delivering cutting-edge treatments for people on Medicaid living with…
Continue Reading
We're excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Dr. George Magrath, CEO at Opus Genetics, practicing ophthalmologist, and someone who’s…
Continue Reading
Promise and Paradox in Cell Therapy Growth
Cell and gene therapies (CGTs) stand at the precipice of transformative growth, with Cardinal Health’s “2025 Advanced Therapies Report” projecting over 200 FDA-approved treatments and 100,000+ U.S. patients…
Biopharmaceutical leaders Pfizer mapped out an exciting journey in AI and gene therapy in the Middle East, Russia and Africa (MERA), as its regional headquarters in Dubai marked their 175th anniversary on Tuesday.
Patrick van…
Scientists at New York University have developed a gene therapy for chronic pain. The technology works by targeting the NaV1.7 sodium ion channel present on neurons, which is an important component of the pain…
Continue Reading
Innovate UK has awarded Sano Genetics a grant of £330k to support the development of a new platform aimed at people who are at risk of the genetic condition motor neurone disease (MND).Light The…
Continue Reading
Gene therapy for hemophilia A patients in the U.S. will have to wait. The FDA needs more time to review data from BioMarin Pharmaceuticals, and the agency told the company it won’t be able…
Continue Reading
Adaptimmune and TCR2 Therapeutics, two clinical-stage biotechs that have recently cut staff to conserve capital, are coming together in a deal that aligns their cell therapy strategies. The business combination also extends the new…
Continue Reading
